Roche and Nurix Therapeutics have announced the two companies will partner in an exclusive licensing and collaboration agreement worth up to $2.3bn.
The collaboration is to co-develop and co-commercialise bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader. The collaboration encompasses a clinical development plan spanning B-cell malignancies, immunology and neurology.
Patients with B-cell–driven malignancies continue to face significant unmet need despite advances with BTK inhibitors and other therapies. In haematology, many patients with CLL ultimately experience disease progression due to acquired resistance mutations, incomplete pathway suppression, or intolerance that limits long-term use, and treatment options remain limited once patients relapse.
Levi Garraway, Roche Chief Medical Officer and Head of Global Product Development, commented: “We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases.”
The addition of bexobrutideg complements Roche’s existing strengths in haematology and provides a cross-therapeutic opportunity to extend the pipeline’s reach in immunology and neurology. Phase 3 clinical trials for bexobrutideg are expected to start in Q2 2026.
Arthur Sands, president and CEO of Nurix Therapeutics, said: “As a single agent, bexobrutideg has shown highly promising results in B cell malignancy clinical trials to date and we can now rapidly expand our phase 3 programme.”
The parties currently expect the transaction to close in the third quarter of 2026.